title: Development of an ALK2-biased BMP type I receptor kinase inhibitor.
abstract: The bone morphogenetic protein (BMP) signaling pathway has essential functions in development, homeostasis, and the normal and pathophysiologic remodeling of tissues. Small molecule inhibitors of the BMP receptor kinase family have been useful for probing physiologic functions of BMP signaling in vitro and in vivo and may have roles in the treatment of BMP-mediated diseases. Here we describe the development of a selective and potent inhibitor of the BMP type I receptor kinases, LDN-212854, which in contrast to previously described BMP receptor kinase inhibitors exhibits nearly 4 orders of selectivity for BMP versus the closely related TGF-β and Activin type I receptors. In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity, and function. LDN-212854 potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. These findings represent a significant step toward developing selective inhibitors targeting individual members of the highly homologous BMP type I receptor family. Such inhibitors would provide greater resolution as probes of physiologic function and improved selectivity against therapeutic targets.
authors.affiliation: Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology , 77 Massachusetts Ave., Cambridge, Massachusetts 02139, United States.
authors.forename: Agustin H
authors.initials: AH
authors.lastname: Mohedas
authors.forename: Xuechao
authors.initials: X
authors.lastname: Xing
authors.forename: Kelli A
authors.initials: KA
authors.lastname: Armstrong
authors.forename: Alex N
authors.initials: AN
authors.lastname: Bullock
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Cuny
authors.forename: Paul B
authors.initials: PB
authors.lastname: Yu
mesh_terms: D030201:Activin Receptors, Type I / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D052005:Bone Morphogenetic Protein Receptors, Type I / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002460:Cell Line; D006801:Humans; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D011720:Pyrazoles / Q000737:chemistry* / Q000494:pharmacology*; D011743:Pyrimidines / Q000737:chemistry* / Q000494:pharmacology*; D011804:Quinolines / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: C000591078:LDN-212854; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D011804:Quinolines; D030201:Activin Receptors, Type I; D052005:Bone Morphogenetic Protein Receptors, Type I
references.citation: Nat Rev Genet. 2003 Oct;4(10):763-73
references.pmid: 14526373
references.citation: Clin Orthop Relat Res. 2007 Sep;462:87-92
references.pmid: 17572636
references.citation: J Biol Chem. 2012 Oct 26;287(44):36990-8
references.pmid: 22977237
references.citation: Oncogene. 1993 Oct;8(10):2879-87
references.pmid: 8397373
references.citation: BMC Cell Biol. 2007 Sep 19;8:41
references.pmid: 17880711
references.citation: J Biol Chem. 2008 Feb 15;283(7):3877-88
references.pmid: 18042551
references.citation: Cancer Sci. 2005 Nov;96(11):791-800
references.pmid: 16271073
references.citation: Nat Med. 2008 Dec;14(12):1363-9
references.pmid: 19029982
references.citation: ACS Chem Biol. 2010 Feb 19;5(2):245-53
references.pmid: 20020776
references.citation: Mucosal Immunol. 2011 Sep;4(5):484-95
references.pmid: 21750585
references.citation: Blood. 2011 Oct 13;118(15):4224-30
references.pmid: 21841161
references.citation: Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92
references.pmid: 18621530
references.citation: Best Pract Res Clin Rheumatol. 2008 Mar;22(1):191-205
references.pmid: 18328989
references.citation: Nat Chem Biol. 2008 Jan;4(1):33-41
references.pmid: 18026094
references.citation: Nat Genet. 2009 Apr;41(4):482-7
references.pmid: 19252486
references.citation: FEBS Lett. 2012 Jul 4;586(14):1993-2002
references.pmid: 22710160
references.citation: Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82
references.pmid: 18000526
references.citation: Toxicol Pathol. 2011 Oct;39(6):916-24
references.pmid: 21859884
references.citation: Toxicol Pathol. 2007 Feb;35(2):284-95
references.pmid: 17366323
references.citation: J Biol Chem. 1994 Jun 24;269(25):16985-8
references.pmid: 8006002
references.citation: J Cell Sci. 1999 Oct;112 ( Pt 20):3519-27
references.pmid: 10504300
references.citation: FEBS Lett. 2012 Jul 4;586(14):1929-41
references.pmid: 22710177
references.citation: Cell Signal. 2011 Nov;23(11):1831-42
references.pmid: 21740966
references.citation: Nat Genet. 2006 May;38(5):525-7
references.pmid: 16642017
references.citation: Nat Biotechnol. 2011 Oct 30;29(11):1046-51
references.pmid: 22037378
references.citation: FEBS Lett. 2012 Jul 4;586(14):1846-59
references.pmid: 22710174
references.citation: Eur J Immunol. 2011 May;41(5):1445-55
references.pmid: 21469090
references.citation: J Biol Chem. 2005 Jul 1;280(26):24443-50
references.pmid: 15883158
references.citation: Mol Pharmacol. 2004 Mar;65(3):744-52
references.pmid: 14978253
references.citation: PLoS One. 2011 Apr 11;6(4):e18365
references.pmid: 21494571
references.citation: ACS Chem Biol. 2013 Jan 18;8(1):96-104
references.pmid: 23276252
references.citation: Genes Dev. 1998 Jul 15;12(14):2144-52
references.pmid: 9679059
references.citation: Blood. 2011 May 5;117(18):4915-23
references.pmid: 21393479
references.citation: Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):409-18
references.pmid: 19914855
references.citation: J Clin Invest. 2004 May;113(9):1271-6
references.pmid: 15124018